

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes the mechanism of action of the novel investigational agent asciminib?
 - a. BTK inhibitor
 - b. BCR-ABL (STAMP) inhibitor
 - c. PD-L1 inhibitor
 - d. PARP inhibitor
2. The Phase III ASCEMBL trial comparing the efficacy of asciminib to bosutinib in patients with chronic myeloid leukemia chronic-phase (CML-CP) previously treated with 2 ATP-binding site tyrosine kinase inhibitors revealed which of the following findings?
 - a. Significant improvement in molecular response with asciminib compared to bosutinib
 - b. Significant improvement in molecular response with bosutinib compared to asciminib
 - c. Increased gastrointestinal toxicities with asciminib compared to bosutinib
 - d. Increased myelosuppression with bosutinib compared to asciminib
3. Which of the following agents is approved for patients with resistant/intolerant CML-CP and/or T315I mutation?
 - a. Imatinib
 - b. Vodobatinib
 - c. Ponatinib
 - d. Bosutinib
4. Which of the following agents has been evaluated as safe for long-term use in patients with CML-CP?
 - a. Asciminib
 - b. Vodobatinib
 - c. Imatinib
 - d. Tafasitamab